Document:

License Agreement, dated December 27, 2002

 Exhibit 10.26 
  
 EXCLUSIVE LICENSE AGREEMENT 
  

between 
  
 THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 
  
 and 
  
 RENOVIS, INC. 
  
 for 
  
 METHOD OF TREATING PAIN USING NALBUPHINE AND OPIOID ANTAGONISTS

  
 UC Case No. 2000-002 
  

	[*]	CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE
406 OF THE SECURITIES EXCHANGE ACT OF 1933, AS AMENDED. 

 UC Case No. SF2000-002 
  
 EXCLUSIVE LICENSE AGREEMENT 
  
 for 
  
 METHOD OF TREATING PAIN USING NALBUPHINE AND OPIOID ANTAGONISTS 
  
 This license agreement (the “Agreement”) is made and entered into effective as of December 27, 2002 (the “Effective Date”) by and
between THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a California corporation having its statewide administrative offices at 1111 Franklin Street, Oakland, California 94607-5200, (“The Regents”), and acting through its Office of Technology
Management, University of California San Francisco, 185 Berry Street, Suite 4603, San Francisco, CA 94107 (“UCSF”), and RENOVIS, INC., a Delaware corporation having a principal place of business at 270 Littlefield Avenue, South San
Francisco, CA 94080 (the “Licensee”). 
  
 BACKGROUND 

 
 A. Certain inventions, generally characterized as “Method of
Treating Pain Using Nalbuphine and Opioid Antagonists” (collectively the “Invention”), were made in the course of research at the University of California San Francisco by Jon D. Levine (the “Inventors”) and are covered by
Regents’ Patent Rights as defined below; 
  
 B. The
development of the Invention was sponsored in part by the National Institutes of Health and as a consequence this license is subject to overriding obligations to the Federal Government under 35 U.S.C. §§200-212 and applicable regulations;

  
 C. The Licensee and The Regents have executed a Letter of
Intent (U.C. Control No. 2001-30-0027) effective February 1, 2001 for the purpose of negotiating a license to Regents’ Patent Rights; 
  
 D. The Licensee wishes to obtain an exclusive license under The Regents’ Patent Rights from The Regents for the commercial research, development,
manufacture, use and sale of 

 
products from the Invention, and The Regents is willing to grant those exclusive rights so that the Invention may be developed to its fullest and the
benefits enjoyed by the general public; and 
  
 E. The Licensee is
a “small business firm” as defined in 15 U.S.C. §632; 
  
 F. Licensee recognizes and agrees that royalties due under this Agreement will be paid on both pending patent applications and issued patents; 
  
 In view of the foregoing, the parties agree: 
  

	1.	DEFINITIONS 

  
 1.1 “Regents’ Patent Rights” means any subject matter claimed in or covered by any of the following: Abandoned U.S. Patent Application Serial No. 60/210,367 entitled “Action of Naloxone on
Gender-dependent Analgesic and Anti-analgesic Effects of Nalbuphine in Humans” filed June 9, 2000 and assigned to The Regents, and pending U.S. Patent Application Serial No. 09/877,669 entitled “Method of Treating Pain Using Nalbuphine and
Opioid Antagonists” filed June 8, 2001 and assigned to The Regents, and, (to the extent legally able to do so and subject to The Regents’ obligations to any providers of third-party materials or funding), any other patent application,
solely to the extent of The Regents’ interest therein, teaching the analgesic uses of kappa opioid agonists and opioid antagonists developed in the laboratory of Jon D. Levine at UCSF and naming Jon D. Levine as a sole or joint inventor and
subsequently filed by or on behalf of The Regents within two years of the Effective Date of this Agreement); and continuing applications thereof including divisions and substitutions and continuation-in-part applications (to the extent the claims
thereof are enabled by and supported by the written description in the disclosure in the parent application); any patents issuing on said applications including reissues, reexaminations and extensions thereof; and any corresponding foreign
applications or patents. 
  
 1.2 “Licensed Product” means any product
(a) that is covered by or claimed in Regents’ Patent Rights, (b) that is produced by the Licensed Method, or (c) the manufacture or use of which is covered by or claimed in Regents’ Patent Rights. 
  
 1.3 “Licensed Method” means any method that is covered by or claimed in
Regents’ Patent Rights. 

 1.4 “Net Sales” means the total of the gross invoice prices of Licensed Products sold or Licensed Methods
performed by the Licensee, an Affiliate, or a sublicensee, less the sum of the following actual deductions where applicable: cash, trade, or quantity discounts, retroactive price reductions or rebates actually granted to customers of Licensed
Products, and charge-back payments and rebased granted to managed health care organizations or to federal, state and local governments (or their respective agencies, purchasers or reimbursers); sales, use, tariff, import/export duties or other
excise taxes imposed on particular sales or services, but excluding value added taxes other than Deductible Value Added Taxes and taxes assessed on income derived from such sales; transportation charges and allowances; or credits to customers
because of recalls, rejections or returns. “Deductible Value Added Tax” means value added tax to the extent such value added tax is actually incurred by the Licensee, an Affiliate, or sublicensee, and is not reimbursable, refundable or
creditable to such party. For purposes of calculating Net Sales, transfers to an Affiliate or sublicensee for end use by the Affiliate or sublicensee will be treated as sales at list price. 
  
 1.5 “Affiliate” means any corporation or other business entity in which the
Licensee owns or controls, directly or indirectly, at least fifty percent (50%) of the outstanding stock or other voting rights entitled to elect directors, or in which the Licensee is owned or controlled directly or indirectly by at least fifty
percent (50%) of the outstanding stock or other voting rights entitled to elect directors; but in any country where the local law does not permit foreign equity participation of at least fifty percent (50%), then an “Affiliate” includes
any company in which the Licensee owns or controls or is owned or controlled by, directly or indirectly, the maximum percentage of outstanding stock or voting rights permitted by local law. 
  
 1.6 “Field of Use” means all human and animal therapeutic and prophylactic
applications and uses. 
  

	2.	LIFE OF PATENT EXCLUSIVE GRANT 

  
 2.1 Subject to the limitations set forth in this Agreement, The Regents grants to the Licensee a world-wide license under Regents’ Patent Rights to practice the
inventions in the Regents’ Patent Rights and to make, have made, use, sell, offer to sell and import Licensed Products and to practice Licensed Methods. 

 2.2 Except as otherwise provided in this Agreement, the license granted in Paragraph 2.1 is exclusive for the life of the
Agreement. 
  
 2.3 The license granted in Paragraphs 2.1 and 2.2 is subject to all
the applicable provisions of any license to the United States Government executed by The Regents and is subject to the overriding obligations to the U.S. Government under 35 U.S.C. §§200-212 and applicable governmental implementing
regulations. 
  
 2.4 The license granted in Paragraphs 2.1 and 2.2 are limited to
methods and products that are within the Field of Use. For other methods and products (if any), the Licensee has no license under this Agreement. 
  
 2.5 The Regents reserves the right to use the Invention and associated technology for educational and academic research purposes. 
  

	3.	SUBLICENSES 

  
 3.1 The Regents also grants to the Licensee the right to issue sublicenses to third parties under the rights granted in Section 2.1, as long as the Licensee has current exclusive rights thereto under this Agreement.
To the extent applicable, sublicenses must include, at a minimum, all of the rights of and obligations due to The Regents (and, if applicable, the United States Government) contained in this Agreement. 
  
 3.2 The Licensee shall promptly provide The Regents with a copy of each sublicense issued,
provided that Licensee may redact from such copy technical information that does not relate to the Regents’ Patent Rights, and economic terms that do not relate to consideration paid for, or other financial obligations relating to, the
grant of the sublicense under the Regents’ Patent Rights ; collect and guarantee payment of all payments due The Regents from sublicensees; and summarize and deliver all reports due The Regents from sublicensees. 
  
 3.3 Upon termination of this Agreement for any reason, The Regents, at its sole discretion,
shall determine whether the Licensee shall cancel or assign to The Regents any and all sublicenses. 
  

	4.	PAYMENT TERMS 

  
 4.1 Paragraphs 1.1, 1.2, and 1.3 define Regents’ Patent Rights, Licensed Products and Licensed Methods so that royalties are payable on products and methods covered by both pending patent 

 
applications and issued patents. Royalties will accrue in each country for the duration of Regents’ Patent Rights in that country and are payable to The
Regents when Licensed Products and/or Licensed Methods are invoiced, or if not invoiced, when delivered to a third party. 
  
 4.2 Licensee shall pay earned royalties quarterly on or before February 28, May 31, August 31 and November 30 of each calendar year. Each payment will be for earned
royalties accrued within the Licensee’s most recently completed calendar quarter. 
  
 4.3 All monies due The Regents are payable in United States dollars. When Licensed Products and/or Licensed Methods are sold for monies other than United States dollars, the Licensee shall first determine the earned royalty in the currency
of the country in which Licensed Products and/or Licensed Methods were sold and then convert the amount into equivalent United States funds, using the exchange rate quoted in the Wall Street Journal on the last business day of the reporting period.

  
 4.4 Royalties earned on sales occurring in any country outside the United
States may not be reduced by any taxes, fees, or other charges imposed by the government of such country on the payment of royalty income. The Licensee is also responsible for all bank transfer charges. Notwithstanding this, all payments made by the
Licensee in fulfillment of The Regents’ tax liability in any particular country (such as by withholding taxes) will be credited against earned royalties or fees due The Regents for that country. 
  
 4.5 If at any time legal restrictions prevent the prompt remittance of royalties by the
Licensee from any country where a Licensed Product and/or Licensed Method is sold, the Licensee shall convert the amount owed to The Regents into United States funds and shall pay The Regents directly from its U.S. source of funds for as long as the
legal restrictions apply. 
  
 4.6 If any patent or patent claim within
Regents’ Patent Rights is held invalid in a final decision by a court of competent jurisdiction and last resort and from which no further appeal can be taken, all obligation to pay royalties based on that patent or claim or any claim patentably
indistinct therefrom will cease as of the date of final decision. The Licensee will not, however, be relieved from paying any royalties that accrued before the final decision or that are based on another patent or claim not involved in the final
decision. 

 4.7 No royalties may be collected or paid on Licensed Products and/or Licensed Methods sold to the account of the U.S.
Government, any agency thereof, state or domestic municipal government as provided for in the License to the Government. 
  
 4.8 If payments, rebillings or fees are not received by The Regents when due, the Licensee shall pay to The Regents interest charges on the above at a rate of ten percent
(10%) per annum. Interest is calculated from the date due until actually received by The Regents. 
  

	5.	LICENSE-ISSUE FEE 

  
 5.1 The Licensee shall pay to The Regents a license-issue fee in the total amount of [*], which amount shall be paid in three (3) equal installments of [*] each, the first installment to be paid within twenty (20)
days after the Effective Date, and the remaining two installments paid on each of the first two anniversaries of the Effective Date. This fee is non-refundable, non-cancelable, and is not an advance against royalties. 
  

	6.	EARNED ROYALTIES 

  
 6.1 The Licensee shall also pay to The Regents an earned royalty equal to a percentage of the Net Sales of Licensed Products and/or Licensed Methods, with the percentage royalty rate determined according to the
following schedule, based upon the level of annual Net Sales of Licensed Products and Licensed Methods worldwide: 
  

	 Annual Net Sales

	  	Royalty Rate

	 Up to $250 million
	  	[*]
	 $250 million to $500 million
	  	[*]
	 Above $500 million
	  	[*]

  
 6.2 With respect to royalties owed to
The Regents due to sales of Licensed Products and/or Licensed Methods by a sublicensee, if the amount of royalties payable to Licensee by such sublicensee based on sublicensee’s Net Sales is less than [*] of Net Sales, then The Regents agree to
negotiate in good faith a reduction of the royalty rate applicable to such sublicensee’s Net Sales, which reduction shall be commercially reasonable and based on the amount of value added by Licensee to such Licensed Product and/or Licensed
Method (including without 

 
limitation preclinical and clinical trial work conducted or funded by Licensee with respect thereto). 
  
 6.3 If Licensee is obligated to pay a third party royalties, based on a license under such
third party’s patent rights, for the manufacture, use, import or sale of a particular Licensed Product or particular Licensed Method, then Licensee shall have the right to credit an amount equal to [*] of the aggregate royalty amounts paid to
the unaffiliated third parties against the royalties owing to The Regents under Section 6.1 above with respect to sales of such Licensed Product or Licensed Method; provided that the credit for any given year does not reduce the royalties owing to
The Regents by more than [*]. 
  
 6.4 Royalty obligations under this Article 6, as
to a particular Licensed Product or Licensed Method, shall expire, on a country-by-country basis, upon the later of: (i) the date of expiration of the last to expire issued patent included in the Regents’ Patent Rights that claims the Licensed
Product or Licensed Method (as applicable) in the particular country, or (ii) ten years after first commercial sale of such Licensed Product or Licensed Method in such country. 
  

	7.	SUBLICENSE REVENUES 

  
 7.1 Licensee shall pay to The Regents royalties based on Net Sales of its sublicensees, as described above in Article 6. In addition, Licensee shall pay to The Regents a percentage (the “Sublicense
Percentage”) of all nonroyalty compensation received by Licensee or its Affiliates (except as otherwise provided below) for the grant of a sublicense under the Regents’ Patent Rights (“Sublicense Revenues”), which percentage
depends on the time of development of the applicable Licensed Product and/or Licensed Method at the time of grant of the sublicense as set forth in the following table: 
  
 [*] 

 However, the above obligation to pay The Regents a share of amounts received from sublicensees shall not apply to any
amounts received as support for research and development activities, as a loan, for the purchase of an equity interest in Licensee, as reimbursement for patent costs, as royalty payments, or as consideration for the grant of rights to intellectual
property and/or materials that are not claimed by the Regents’ Patent Rights. 
  
 7.2 Licensee shall pay to The Regents the applicable share of Sublicensee Revenues within thirty (30) days of receipt of the particular Sublicensee Revenues. 
  

	8.	MILESTONE PAYMENTS 

  
 8.1 With respect to development of Licensed Products and/or Licensed Methods by Licensee or its Affiliate, Licensee shall pay The Regents milestone payments for the first Licensed Product and/or Licensed Method to
achieve the following milestone events for each separate and distinct Medical Indication (as defined below) that such Licensed Product or such Licensed Method is being developed for: 
  

	 Milestone Event

	  	Payment

	 First filing of IND
 First Phase III Trial
 First filing of NDA
 Regulatory Approval
	  	 [*]
 [*]
 [*]
 [*]

  
 A distinct “Medical
Indication” shall mean a particular disease or condition that is recognized in the Merck Manual of Diagnosis and Therapy as a distinct disease or condition for which a drug therapy can be developed and prescribed as a labeled indication, which
disease or condition is different and distinct from any other Medical Indication for which a Licensed Product or Licensed Method is, at the particular time, being clinically developed or marketed. For clarity, 

 
Licensee shall pay the above milestone payments only once as to any particular milestone event for a particular Medical Indication. 
  
 8.2 If Licensee is obligated to pay milestone payments to a third party based on a license
agreement granting Licensee rights to such third party’s intellectual property that covers the Licensed Product and/or Licensed Methods or their manufacture, sale, or use, then the foregoing milestone payments shall be [*] of the amount of such
third party payments, subject to a [*] of the milestone amount set forth above. 
  
 8.3 In addition, Licensee shall pay The Regents a one-time milestone payment of [*] upon Licensee, its Affiliates and/or sublicensees first achieving cumulative gross sales of Licensed Products and/or Licensed Methods in the total amount of
[*]. 
  
 8.4 Milestone payments shall be paid by Licensee within thirty (30) days
of achieving the particular event for which the payment is owed. 
  

	9.	DUE DILIGENCE 

  
 9.1 Commencing on execution of this Agreement, Licensee shall diligently proceed (itself or its Affiliates or sublicensees) with the development of Licensed Products and/or Licensed Methods with the goal of achieving
regulatory approval for marketing thereof as soon as practicable, using commercially reasonable efforts. Upon achieving such approval, Licensee (or its Affiliate or sublicensee) shall use diligent efforts to manufacture and sell such approved
License Product and/or Licensed Method and shall earnestly and diligently endeavor to market the same in quantities sufficient to meet market demands. Licensee will be entitled to exercise prudent and reasonable business judgment in meeting its due
diligence obligations hereunder. 
  
 9.2 The Licensee shall endeavor, using
commercially reasonable efforts, to obtain all necessary governmental approvals for the manufacture, use and sale of Licensed Products and/or Licensed Methods. 
  

9.3 Subject to Section 9.6, the Licensee shall: 
  
 9.3.1 submit an IND covering Licensed Products to the United States FDA within [*] from the Effective Date of this Agreement; 
  
 9.3.2 obtain regulatory approval to market a Licensed Product within [*]
from the Effective Date of this Agreement; and 

 9.3.3 market Licensed Products in the United States within [*] of receiving regulatory approval of such
Licensed Product from the FDA. 
  
 9.4 If the Licensee is unable timely to perform
any of the above provisions (as such time deadlines may be extended as provided in Section 9.5 below), then The Regents has the right and option to either terminate this Agreement or reduce the Licensee’s exclusive license to a non exclusive
license. This right, if exercised by The Regents, supersedes the rights granted in Article 2 (GRANT). 
  
 9.5 If Licensee is unable to meet any of its due diligence obligations set forth in Section 9.3 within the specified time, then Licensee will have the right and option to extend the target date of any such due
diligence obligation for a period of [*] upon the payment of [*] within thirty (30) days of the extension date for each such extension option exercised by Licensee. Licensee may further extend the target date of any diligence obligation for an
additional [*] upon payment of an additional [*]. Both [*] extensions will automatically apply unless Licensee notifies The Regents in writing prior to the target date that Licensee does not elect to take the extension. Additional extensions may be
granted only by mutual written agreement of the parties to this Agreement. 
  
 9.6
Licensee shall be deemed to meet the applicable milestones in Section 9.3 above if Licensee (and/or its Affiliate or sublicensee) spends not less than three hundred thousand dollars ($300,000) per year during the first three (3) years of this
Agreement for the development of one or more Licensed Products and/or Licensed Methods, and during the following five (5) years of this Agreement, an amount that averages out to be (when measured at any particular time during such five (5) year
period) spending at a rate at such time that equals at least six hundred thousand dollars ($600,000) per year up until such time, for the development and/or marketing of one or more Licensed Products and/or Licensed Methods , provided that the
foregoing shall terminate upon filing of an NDA or foreign equivalent application covering a Licensed Product or Licensed Method. 
  

	10.	PROGRESS AND ROYALTY REPORTS 

  
 10.1 Beginning August 31, 2003 and semi-annually thereafter, the Licensee shall submit to The Regents a progress report covering the Licensee’s (and any
Affiliate’s or sublicensee’s) activities related to the development and testing of all Licensed Products and/or Licensed Methods and the obtaining of the governmental approvals necessary for marketing. Progress reports are required 

 
for each Licensed Product and Licensed Method until the first commercial sale of that Licensed Product or that Licensed Method occurs in the United States
and shall be again required if commercial sales of such Licensed Product or Licensed Method are suspended or discontinued. 
  
 10.2 Progress reports submitted under Paragraph 10.1 shall include, but are not limited to, the following topics: 
  

	 	–	summary of work completed 

  

	 	–	key scientific discoveries 

  

	 	–	summary of work in progress 

  

	 	–	current schedule of anticipated events or milestones 

  

	 	–	market plans for introduction of Licensed Products and/or Licensed Methods, and 

  

	 	–	a summary of resources [*] spent in the reporting period. 

  
 10.3 The Licensee has a continuing responsibility to keep The Regents informed of the large/small business entity status (as defined by the United States Patent and
Trademark Office) of itself and its sublicensees and Affiliates. 
  
 10.4 The
Licensee shall report to The Regents the date of first commercial sale of a Licensed Product and/or Licensed Method in each country in its immediately subsequent progress and royalty report. 
  
 10.5 After the first commercial sale of a Licensed Product and/or Licensed Method anywhere in
the world, the Licensee shall make quarterly royalty reports to The Regents on or before each February 28, May 31, August 31 and November 30 of each year. Each royalty report will cover the Licensee’s most recently completed calendar quarter
and will show (a) the gross sales and Net Sales of Licensed Products and/or Licensed Methods sold during the most recently completed calendar quarter; (b) the number of each type of Licensed Product and/or Licensed Method sold; (c) the royalties, in
U.S. dollars, payable with respect to sales of Licensed Products and/or Licensed Methods; (d) the method used to calculate the royalty; and (e) the exchange rates used. 
  
 10.6 If no sales of Licensed Products and/or Licensed Methods have been made during any reporting period, a statement to this effect is
required. 

	11.	BOOKS AND RECORDS 

  
 11.1 The Licensee shall keep accurate books and records showing all Licensed Products and/or Licensed Methods manufactured, used, and/or sold under the terms of this Agreement. Books and records must be preserved for
at least three (3) years from the date of the royalty payment to which they pertain. 
  
 11.2 Such books and records shall be made available by Licensee for inspection by an independent auditor with a national auditing firm engaged by The Regents and reasonably acceptable to Licensee, solely to confirm the royalty payments and
other payments made hereunder. Such auditor shall not disclose Licensee’s Confidential Information, except to the extent such disclosure is necessary to verify the portion of the amount of royalties and payments due under this Agreement. Such
audits may be exercised once a year, within three (3) years after the period to which such records relate, upon at least 30 days written notice to Licensee and during normal business hours. The Regents shall bear the fees and expenses of such
examination, unless the audit reveals an underpayment of royalties of more than five percent (5%) of the total royalties due for the period examined, in which case the Licensee shall bear the fees and expenses of that examination. 
  

	12.	LIFE OF THE AGREEMENT 

  
 12.1 Unless otherwise terminated by operation of law or by acts of the parties in accordance with the terms of this Agreement, this Agreement will be in force from the Effective Date until the last-to-expire patent
licensed under this Agreement; or until the last patent application licensed under this Agreement is abandoned and no patent in Regents’ Patent Rights ever issues. 
  
 12.2 Any termination of this Agreement will not affect the rights and obligations set forth in the following Articles: 
  

	 Article 11
 Article 15
 Article 16
 Article 21
 Article 24
 Article 30
	  	 Books and Records
 Disposition of Licensed Products on Hand on Termination
 Use of Names and Trademarks
 Indemnification
 Failure to Perform
 Secrecy

	13.	TERMINATION BY THE REGENTS 

  
 13.1 In addition to the termination provision of Section 9.4 herein, if the Licensee fails to perform or violates any material term of this Agreement, then The Regents may give written notice of default (Notice of
Default) to the Licensee. If the Licensee fails to repair the default within sixty (60) days of the effective date of Notice of Default, The Regents may terminate this Agreement and its licenses by a second written notice (Notice of Termination). If
a Notice of Termination is sent to the Licensee, this Agreement will automatically terminate on the effective date of that notice. Termination will not relieve the Licensee of its obligation to pay any fees owing at the time of termination and will
not impair any accrued right of The Regents. These notices are subject to Article 22 (Notices). 
  

	14.	TERMINATION BY LICENSEE 

  
 14.1 The Licensee has the right at any time to terminate this Agreement in whole or as to any portion of Regents’ Patent Rights by giving notice in writing to The Regents. Notice of termination will be subject to
Article 22 (Notices) and termination of this Agreement will be effective sixty (60) days from the effective date of notice. 
  
 14.2 Any termination under the above paragraph does not relieve the Licensee of any obligation or liability accrued under this Agreement prior to termination or rescind
any payment made to The Regents or anything done by Licensee prior to the time termination becomes effective. Termination does not affect in any manner any rights of The Regents arising under this Agreement prior to termination. 
  

	15.	DISPOSITION OF LICENSED PRODUCTS ON HAND UPON TERMINATION 

  
 15.1 Upon termination of this Agreement, the Licensee and its Affiliates are entitled to dispose of all previously made or partially made Licensed Products, but no more,
within a period of one hundred and twenty (120) days provided that the sale of those Licensed Products is subject to the terms of this Agreement, including but not limited to the rendering of reports and payment of royalties required under this
Agreement. 

	16.	USE OF NAMES AND TRADEMARKS 

  
 16.1 Nothing contained in this Agreement confers any right to use in advertising, publicity, or other promotional activities any name, trade name, trademark, or other designation of either party hereto (including
contraction, abbreviation or simulation of any of the foregoing). Unless required by law, the use by the Licensee of the name “The Regents of the University of California” or the name of any campus of the University of California is
prohibited. 
  

	17.	LIMITED WARRANTY 

  
 17.1 The Regents warrants to the Licensee that it has the lawful right to grant this license. 
  
 17.2 This license and the associated Invention are provided WITHOUT WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR ANY OTHER WARRANTY, EXPRESS OR
IMPLIED. THE REGENTS MAKES NO REPRESENTATION OR WARRANTY THAT THE LICENSED PRODUCTS OR LICENSED METHODS WILL NOT INFRINGE ANY PATENT OR OTHER PROPRIETARY RIGHT. 
  

17.3 IN NO EVENT SHALL EITHER PARTY BE LIABLE TO THE OTHER PARTY FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE
USE OF THE INVENTION OR LICENSED PRODUCTS OR LICENSED METHODS OR ANY OTHER CLAIM ARISING UNDER THIS AGREEMENT, EXCEPT THAT LICENSEE SHALL BE LIABLE FOR ANY INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES RESULTING FROM EXERCISE OF THIS LICENSE OR THE
USE OF THE INVENTION OR LICENSED PRODUCTS OR LICENSED METHODS OR ANY OTHER CLAIM ARISING UNDER THIS AGREEMENT WHEN LICENSEE MUST INDEMNIFY, HOLD HARMLESS, AND DEFEND THE REGENTS UNDER ARTICLE 21 (INDEMNIFICATION). 
  
 17.4 This Agreement does not: 
  
 17.4.1 express or imply a warranty or representation as to the validity or scope of any of Regents’ Patent Rights;

  
 17.4.2 express or imply a warranty or representation that
anything made, used, sold, offered for sale or imported or otherwise disposed of under any license granted in this Agreement is or will be free from infringement of patents of third parties; 

 17.4.3 obligate The Regents to bring or prosecute actions or suits against third parties for patent
infringement except as provided in Article 20; 
  
 17.4.4 confer
by implication, estoppel or otherwise any license or rights under any patents of The Regents other than Regents’ Patent Rights as defined in this Agreement, regardless of whether those patents are dominant or subordinate to Regent’s Patent
Rights; or 
  
 17.4.5 obligate The Regents to furnish any
know-how not provided in Regents’ Patent Rights. 
  

	18.	PATENT PROSECUTION AND MAINTENANCE 

  
 18.1 As long as the Licensee has paid patent costs as provided for in this Article, The Regents shall diligently endeavor to prosecute and maintain the United States and
foreign patents and patent applications comprising Regents’ Patent Rights using counsel of its choice reasonably acceptable to Licensee, and The Regents shall provide the Licensee, at a reasonable time in advance of any filing or correspondence
with relevant patent offices or agencies, with copies of all relevant documentation and communications so that the Licensee may be informed of the continuing prosecution and shall have the opportunity to comment thereon. The Regents agrees to use
diligent efforts to accommodate all of Licensee’s reasonable comments on such prosecution efforts. Licensee agrees to keep this documentation confidential. The Regents’ counsel will take instructions only from The Regents, and all patents
and patent applications under this Agreement will be assigned solely to The Regents. 
  
 18.2 The Regents shall use all reasonable efforts to amend any patent application to include claims reasonably requested by the Licensee to protect the products contemplated to be sold under this Agreement. 
  
 18.3 The Licensee shall apply for an extension of the term of any patent included within
Regents’ Patent Rights if appropriate under the Drug Price Competition and Patent Term Restoration Act of 1984 and/or European, Japanese and other foreign counterparts of this Law. The Licensee shall prepare all documents, and The Regents
agrees to execute the documents and to take additional action as the Licensee reasonably requests in connection therewith. 
  
 18.4 The Licensee shall bear [*] costs of preparing, filing, prosecuting and maintaining all United States and foreign patent applications contemplated by this Agreement.
Costs billed by 

 
The Regents’ counsel will be rebilled to the Licensee and are due within thirty (30) days of rebilling by The Regents. These costs include patent
prosecution costs for the Invention incurred by The Regents prior to the execution of this Agreement and [*] patent prosecution costs that may be incurred for patentability opinions, re-examination, re-issue, interferences, or inventorship
determinations. Licensee has paid to date [*] prior costs and expenses for such prosecution efforts that have been invoiced to Licensee prior to             , 2002, and Licensee
shall pay within thirty (30) days of execution of this Agreement [*] additional costs and expenses for such efforts that have been invoiced to Licensee as of the Effective Date. For the avoidance of doubt, Licensee will continue to pay costs and
expenses for prosecution efforts as they are invoiced to Licensee. 
  
 18.5 The
Licensee may request The Regents to obtain patent protection on the Invention in foreign countries if available and if it so desires. The Licensee shall notify The Regents of its decision to obtain or maintain foreign patents not less than sixty
(60) days prior to the deadline for any payment, filing, or action to be taken in connection therewith. This notice concerning foreign filing must be in writing, must identify the countries desired, and must reaffirm the Licensee’s obligation
to underwrite the costs thereof. The absence of such a notice from the Licensee to The Regents will be considered an election not to obtain or maintain foreign rights. 
  
 18.6 The Licensee’s obligation to [*] and to pay patent prosecution costs will continue for so long as this Agreement remains in
effect, but the Licensee may terminate its obligations with respect to any given patent application or patent upon thirty (30) days written notice to The Regents. The Regents will use its best efforts to curtail patent costs when a notice of
termination is received from the Licensee. The Regents may prosecute and maintain such application(s) or patent(s) at its sole discretion and expense, but the Licensee will have no further right or licenses thereunder. Non-payment of patent costs
may be deemed by The Regents as an election by the Licensee not to maintain application(s) or patent(s). 
  
 18.7 The Regents may file, prosecute or maintain patent applications at its own expense in any country in which the Licensee has not elected to file, prosecute, or maintain patent applications in accordance with this
Article, and those applications and resultant patents will not be subject to this Agreement. If The Regents elect not to file, prosecute or maintain any particular patent application or patent within the Regents’ Patent Rights in any country in
which the Licensee has 

 
elected to file, prosecute, or maintain such patent applications in accordance with this Article, to the extent legally able to do so, then The Regents shall
provide Licensee the right at its expense to undertake such filing, prosecution and maintenance in the name of The Regents, and The Regents shall cooperate in all reasonable manners to assist such efforts (at no expense to The Regents). 

 

	19.	PATENT MARKING 

  
 19.1 The Licensee, its Affiliates, and sublicensees shall mark all Licensed Products and/or Licensed Methods made, used or sold under the terms of this Agreement, or their containers, to the extent required by the
applicable patent marking laws. 
  

	20.	PATENT INFRINGEMENT 

  
 20.1 In the event that The Regents (to the extent of the actual knowledge of the licensing professional responsible for the administration of this Agreement) or the Licensee learns of infringement of potential
commercial significance of any patent licensed under this Agreement, the knowledgeable party will provide the other (i) with written notice of such infringement and (ii) with any evidence of such infringement available to it (the “Infringement
Notice”). During the period in which, and in the jurisdiction where, the Licensee has exclusive rights under this Agreement, neither The Regents nor the Licensee will notify a third party (including the infringer) of infringement or put such
third party on notice of the existence of any Patent Rights without first obtaining consent of the other, provided that Licensee shall have the right to notify such third party to the extent that Licensee has, under Section 20.2, the right to
initiate suit against such third party for infringement. The Regents shall have the right to terminate this Agreement immediately without the obligation to provide 60 days’ notice as set forth in Paragraph 13.1 if the Licensee notifies a third
party of infringement or puts such third party on notice of the existence of any Regents’ Patent Rights with respect to such infringement to the extent Licensee is required to first obtain the written consent of The Regents, as set forth above.
Both The Regents and the Licensee will use their diligent efforts to cooperate with each other to terminate such infringement without litigation. 

 20.2 If infringing activity of potential commercial significance by the infringer has not been abated within ninety (90)
days following the date the Infringement Notice takes effect, the Licensee may institute suit for patent infringement against the infringer. The Regents may voluntarily join such suit at its own expense, but may not thereafter commence suit against
the infringer for the acts of infringement that are the subject of the Licensee’s suit or any judgment rendered in that suit. The Licensee may not join The Regents as a party to a suit initiated by the Licensee without The Regents’ prior
written consent. If, in a suit initiated by the Licensee, The Regents is involuntarily joined other than by the Licensee, the Licensee will pay any costs incurred by The Regents arising out of such suit, including but not limited to, any legal fees
of counsel that The Regents selects and retains to represent it in the suit. 
  
 20.3 If, within a hundred and twenty (120) days following the date the Infringement Notice takes effect, infringing activity of potential commercial significance by the infringer has not been abated and if the Licensee has not brought suit
against the infringer, The Regents may institute suit for patent infringement against the infringer. If The Regents institutes such suit, the Licensee may not join such suit without The Regents’ consent and may not thereafter commence suit
against the infringer for the acts of infringement that are the subject of The Regents’ suit or any judgment rendered in that suit. 
  
 20.4 Any recovery or settlement received in connection with any suit will first be shared by The Regents and the Licensee equally to cover the litigation costs each
incurred, and next shall be paid to The Regents or the Licensee to cover any litigation costs it incurred in excess of the litigation costs of the other. In any suit initiated by the Licensee, any recovery in excess of litigation costs will be
shared between the Licensee and The Regents as follows: (a) for any such recovery by Licensee based on claims made by Licensee funded by Licensee in litigation to which The Regents is not a party, other than amounts paid for willful infringement,
such recovery shall be deemed Net Sales for which Licensee shall pay the Regents royalties pursuant to Section 6.1; (b) for any such recovery by Licensee based on claims made by Licensee funded by Licensee in litigation to which The Regents is a
party other than amounts paid for willful infringement, such recovery shall be [*] to The Licensee and [*] to The Regents, (c) for any such recovery by Licensee based on claims made by Licensee and The Regents funded by Licensee and The Regents in
litigation to which The Regents is a party, other than amounts paid to willful 

 
infringement, such recovery shall be shared according to actual litigation costs and expenses borne by the parties, with a minimum share to The Regents of
[*] regardless of a lesser percentage of costs and expenses borne by The Regents, and (d) for any recovery for willful infringement The Regents shall receive [*] of the recovery. In any suit initiated by The Regents, any recovery in excess of
litigation costs will belong to The Regents. The Regents and the Licensee agree to be bound by all determinations of patent infringement, validity, and enforceability (but no other issue) resolved by any adjudicated judgment in a suit brought in
compliance with this Article 20. 
  
 20.5 Any agreement made by the Licensee for
purposes of settling litigation or other dispute shall comply with all of the requirements regarding sublicensing specified in this Agreement, including but not limited to Articles 3, 7, 8, 9, and 10. 
  
 20.6 Each party will cooperate with the other in litigation proceedings instituted hereunder
but at the expense of the party who initiated the suit (unless such suit is being jointly prosecuted by the parties). 
  
 20.7 Any litigation proceedings will be controlled by the party bringing the suit, except that The Regents may be represented by counsel of its choice in any suit brought
by the Licensee. 
  

	21.	INDEMNIFICATION 

  
 21.1 The Licensee shall indemnify, hold harmless and defend The Regents, its officers, employees, and agents; the sponsors of the research that led to the Invention; and the inventors of the patents and patent
applications in Regents’ Patent Rights and their employers against any and all third party claims, suits, losses, liabilities, damages, costs, fees, and expenses resulting from or arising out of exercise of this license or any sublicense. This
indemnification includes, but is not limited to, any product liability. 
  
 21.2
The Licensee, at its sole cost and expense, shall insure its activities in connection with the work under this Agreement and obtain, keep in force and maintain insurance as follows, or an equivalent program of self insurance: 
  
 21.3 Comprehensive or commercial form general liability insurance (contractual liability
included) with limits as follows: 
  

	 	–	Each Occurrence [*] 

	 	–	Products/Completed Operations Aggregate [*] 

  

	 	–	Personal and Advertising Injury [*] 

  

	 	–	General Aggregate (commercial form only) [*] 

  
 The coverage and limits referred to under the above do not in any way limit the liability of the Licensee. The Licensee shall furnish The Regents with
certificates of insurance showing compliance with all requirements. Certificates must: 
  

	 	–	Provide for thirty (30) days’ advance written notice to The Regents of any modification. 

  

	 	–	Indicate that The Regents has been endorsed as an additional Insured under the coverage referred to under the above. 

  

	 	–	Include a provision that the coverage will be primary and will not participate with nor will be excess over any valid and collectable insurance or program of self-insurance carried
or maintained by The Regents. 

  
 21.4 The Regents shall notify the
Licensee in writing of any claim or suit brought against The Regents in respect of which The Regents intends to invoke the provisions of this Article. The Licensee shall keep The Regents informed on a current basis of its defense of any claims under
this Article. 
  

	22.	NOTICES 

  
 22.1 Any notice or payment required to be given to either party is properly given and effective (a) on the date of delivery if delivered in person or (b) five (5) days after mailing if mailed by first-class certified
mail, postage paid, to the respective addresses given below, or to another address as is designated by written notice given to the other party. 
  

	In the case of the Licensee:	  	 Renovis, Inc.
 270 Littlefield Avenue
 South San Francisco, CA 94080
 Attention: President

		
	 With a copy to:
	  	 Cooley Godward LLP
 Five Palo Alto Square
 3000 El Camino Real
 Palo Alto, CA 94306
 Attn: Barclay James Kamb, Esq.

		
	 In the case of The Regents:
	  	 Office of Technology Management
 University of California San Francisco
 185 Berry Street, Suite 4603
 San Francisco, CA 94107
 Attention: Director
 Referring to: UCSF Case No. SF-2000-002

	
	 In the case of The Regents, for accounting and payment purposes:

	 	  	 Office of Technology Transfer
 Attn.: Accounts Receivable (UCSF Case No. 2000-002)
 University of California
 Office of the President
 1111 Franklin Street, 7th Floor
 Oakland, CA 94607-5200

  

	23.	ASSIGNABILITY 

  
 23.1 This Agreement may be assigned by The Regents, but is personal to the Licensee and assignable by the Licensee only with the written consent of The Regents, which consent will not be unreasonably withheld;
provided, however, that Licensee may assign this Agreement without such consent to its successor in interest pursuant to a merger, acquisition, sale of all or substantially all of its assets to which this Agreement relates or similar
transaction. 
  

	24.	FAILURE TO PERFORM 

  
 24.1 If either party finds it necessary to undertake legal action against the other on account of failure of performance due under this Agreement, then the prevailing party is entitled to reasonable attorney’s
fees in addition to costs and necessary disbursements. 
  

	25.	NO WAIVER 

  
 25.1 No waiver by either party of any default of this Agreement may be deemed a waiver of any subsequent or similar default. 
  

	26.	GOVERNING LAWS 

  
 26.1 THIS AGREEMENT WILL BE INTERPRETED AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF CALIFORNIA, but the scope and 

 
validity of any patent or patent application will be governed by the applicable laws of the country of the patent or patent application. 
  

	27.	PREFERENCE FOR UNITED STATES INDUSTRY 

  
 27.1 Because this Agreement grants the exclusive right to use or sell the Invention in the United States, the Licensee agrees that any products sold in the U.S. embodying
this Invention or produced through the use thereof will be manufactured substantially in the United States, unless a waiver from the foregoing requirement is obtained as permitted under applicable law or regulation. The Regents agree that, if
requested by Licensee, The Regents will use reasonable and good faith efforts to seek a waiver or exception from the foregoing requirement, on reasonable showing of need therefore by Licensee. 
  

	28.	GOVERNMENT APPROVAL OR REGISTRATION 

  
 28.1 Licensee shall notify The Regents if it becomes aware that this Agreement is subject to any U.S. or foreign government reporting or approval requirement. Licensee
shall make all necessary filings and pay all costs including fees, penalties, and all other out-of-pocket costs associated with such reporting or approval process. 
  

	29.	EXPORT CONTROL LAWS 

  
 29.1 The Licensee and its Affiliates shall observe all applicable United States and foreign laws with respect to the transfer of Licensed Products and/or Licensed Methods and related technical data to foreign
countries, including, without limitation, the International Traffic in Arms Regulations (ITAR) and the Export Administration Regulations. 

	30.	SECRECY 

  
 30.1 With regard to confidential information received by Licensee from The Regents regarding the Invention and identified by The Regents as “confidential” on disclosure to Licensee, or confidential
information of Licensee disclosed to The Regents and identified as “confidential” on disclosure to The Regents (in each case, the “Confidential Information” of the disclosing party), the receiving Party agrees, subject to Section
29.2: 
  
 30.1.1 not to use the Confidential Information of the
disclosing Party for any purpose except for the sole purpose of performing under the terms of this Agreement; 
  
 30.1.2 to safeguard such Confidential Information against disclosure to others with the same degree of care as it exercises with its own data of a similar
nature; 
  
 30.1.3 not to disclose such Confidential Information
to others (except to its employees, agents, consultants or sublicensees who are bound to the Party by a like obligation of confidentiality) without the express written permission of the disclosing Party. 
  
 Further, the Parties agree that, subject to the exceptions provided in Section 29.2 below,
all information communicated by a party (or its counsel) to the other party hereunder regarding prosecution of the patent applications in the Regents’ Patent rights shall be deemed to be “Confidential Information” of the disclosing
party, and that the failure on the part of that party or its counsel to mark as “Confidential” any communication between such party and its counsel, shared under attorney-client privilege, shall not negate the confidential nature of such
correspondence or the receiving Party’s obligation to treat such information as “Confidential Information” if and from the time that such is disclosed to receiving Party. 
  
 30.2 The obligations under Section 29.1 shall not apply to any Confidential Information of a disclosing Party if the receiving Party can
demonstrate by competent evidence that such Confidential Information: 
  

	 	30.2.1	was previously known to the receiving Party prior to disclosure hereunder; 

  

	 	30.2.2	is now, or becomes in the future, public knowledge other than through acts or omissions of the receiving Party; 

  

	 	30.2.3	is lawfully obtained by the receiving Party from sources independent of the disclosing Party; or 

  

	 	30.2.4	is independently developed by the receiving Party without use of the Confidential Information of the disclosing Party. 

 30.3 The obligations of the Parties with respect to Confidential Information will continue for a period ending [*] from
the termination date of this Agreement, subject to Section 29.4. 
  
 30.4 The
non-disclosure obligations contained in Section 29.1 shall not apply to particular Confidential Information that a Party received from the other Party to the extent that such receiving Party is required to disclose such Confidential Information by
law, order or regulation of a governmental agency (including the California Public Records Act or governmental audit requirement) or a court of competent jurisdiction, provided that such Party shall first give reasonable notice of such
requirement to the other Party and shall seek, or cooperate in such other Party’s efforts in obtaining, a protective order or confidential treatment of such Confidential Information, and shall in any event disclose only the minimum amount of
information as is required. 
  

	31.	MISCELLANEOUS 

  
 31.1 The headings of the several sections are inserted for convenience of reference only and are not intended to be a part of or to affect the meaning or interpretation of this Agreement. 
  
 31.2 This Agreement is not binding on the parties until it has been signed below on behalf of
each party. It is then effective as of the Effective Date. 
  
 31.3 No amendment
or modification of this Agreement is valid or binding on the parties unless made in writing and signed on behalf of each party. 
  
 31.4 This Agreement embodies the entire understanding of the parties and supersedes all previous communications, representations or understandings, either oral or
written, between the parties relating to the subject matter hereof. In case any of the provisions contained in this Agreement is held to be invalid, illegal, or unenforceable in any respect, that invalidity, illegality or unenforceability will not
affect any other provisions of this Agreement, and this Agreement will be construed as if the invalid, illegal, or unenforceable provisions had never been contained in it. 

 IN WITNESS WHEREOF, both The Regents and the Licensee have executed this Agreement, in duplicate
originals, by their respective and duly authorized officers on the day and year written. 
  

	 RENOVIS, INC.
	 	 	 	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
					
	By:	 	 /s/    LYNN
ZYDOWSKY        

	 	 	 	By:	 	 /s/    JOEL B.
KIRSCHBAUM        

	 	 	(Signature)	 	 	 	 	 	(Signature)
					
	 Name:
	 	 LYNN ZYDOWSKY

	 	 	 	Name:	 	 JOEL B. KIRSCHBAUM

	 	 	(Please Print)	 	 	 	 	 	(Please Print)
					
	 Title:
	 	 SVP Corporate Development

	 	 	 	 Title:
	 	 Director OTM

					
	 Date:
	 	 12/27/02

	 	 	 	Date:	 	 12/27/02Employment Agreement dated as of November 15, 2002 - F. Jacob Huff, M.D.

 EXHIBIT 10.33 
  
 [GRAPHIC APPEARS HERE] 
  
 November 15, 2002 
  
 F. Jacob Huff, M.D. 
  
 Re: Employment Terms 
  
 Dear Jay: 
  
 I am extremely pleased to offer you the position of Vice President, Clinical Development and I look forward to your favorable reply. Please review the following
employment terms: 
  
 You will be responsible for working as Vice President,
Clinical Development and will report to me. In this position, the regulatory affairs function will also report to you. You will work at our facility located at 270 Littlefield, South San Francisco, CA. However, during your transition period you may
also work from your home in Laguna Hills. Of course, Renovis may change your position, reporting structure, duties, and work location from time to time as it deems necessary. 
  
 Your full-time compensation will be $200,000 per year, less payroll deductions and all required withholdings. You will also be eligible for
an annual bonus of up to 25% of annual salary. To accommodate your transition, we agree that your commitment will be at the 50% level as of your start date of December 11, 2002. This will increase to 75% by January 1, 2003 and to 100% no later than
June 30, 2003. In addition, you will be granted an option to purchase 150,000 shares of the company’s common stock, as governed by the terms of the Company’s stock option plan, at a price to be determined by and subject to approval of the
Company’s Board of Directors. Your stock options will vest at a rate of 37,500 shares as of the first anniversary of your start date and 3,125 shares per calendar month thereafter. 
  
 You will also be eligible for the following standard Company benefits as of your start date of December 1, 2002: medical insurance,
vacation, 401(k) plan, sick leave, and holidays. (Please see attached summary). Details about these benefit plans are available for your review; however, please note that Renovis may modify compensation and benefits from time to time as it deems
necessary. 
  
 To facilitate your joining Renovis, the company will reimburse you
up to $75,000 in travel-related expenses during the above transition period as well as relocation-related expenses. Typical relocation expenses include costs associated with the movement of household goods 

 F. Jacob Huff, M.D. 
 November 15, 2002 
 Page 2 
  
 and automobile, temporary housing, and the down payment on the
purchase of a home in the Bay Area. 
  
 As a Renovis employee, you will be
expected to abide by Company rules and policies, acknowledge in writing that you have read the Company’s Employee Handbook, and sign and comply with the attached Proprietary Information and Inventions Agreement which prohibits unauthorized use
or disclosure of Renovis proprietary information. 
  
 In your work for the
Company, you will be expected not to use or disclose any confidential information, including trade secrets, of any former employer or other person to whom you have an obligation of confidentiality. Rather, you will be expected to use only that
information which is generally known and used by persons with training and experience comparable to your own, which is common knowledge in the industry or otherwise legally in the public domain, or which is otherwise provided or developed by the
Company. During our discussions about your proposed job duties, you assured us that you would be able to perform those duties within the guidelines just described. 
  
 You agree that you will not bring onto Company premises any unpublished documents or property belonging to any former employer or other
person to whom you have an obligation of confidentiality. 
  
 When your employment
reaches the 100% level, normal business hours are from 8:30 a.m. to 5:30 p.m., Monday through Friday. As an exempt salaried employee, you will be expected to work additional hours as required by the nature of your work assignments. 
  
 You may terminate your employment with Renovis at any time and for any reason whatsoever
simply by notifying Renovis. Likewise, Renovis may terminate your employment at any time and for any reason whatsoever, with or without cause or advance notice. This at-will employment relationship cannot be changed except in writing signed by a
Company officer. 
  
 This letter, together with your Proprietary Information and
Inventions Agreement, forms the complete and exclusive statement of your employment agreement with Renovis. The employment terms in this letter supersede any other agreements or promises made to you by anyone, whether oral or written. As required by
law, this offer is subject to satisfactory proof of your right to work in the United States. 
  
 Please sign and date this letter, and return it to me by November 21, 2002, if you wish to accept employment at Renovis under the terms described above. 

 F. Jacob Huff, M.D. 
 November 15, 2002 
 Page 3 
  
 I want you to know how enthusiastic we are to have you on the Renovis team. It’s a great opportunity for Renovis and a great opportunity for you. We look forward to
working with you. I look forward to speaking with you soon! 
  
 Sincerely,

  

	 /s/ Corey Goodman

	 Corey Goodman, Ph.D.

	 President & Chief Executive Officer

	
	 Accepted:

	
	 /s/ F. Jacob Huff

	 20 November 2002

	 Date

  
 Attachments: Proprietary Information
and Inventions Agreement; Benefits Summary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00060-of-00352.parquet"}]]